Selenium Compounds Targeting Akt3 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer treatments are inadequate in effectively inhibiting abnormal cell survival and proliferation, particularly in melanoma, due to limitations in targeting the Akt3 signaling cascade, iNOS, and MAP kinase pathways, leading to poor survival rates and systemic toxicity.
Innovation Solution
Development of selenium-containing compounds with specific structural formulas that inhibit the Akt3 signaling cascade, block cell cycle progression, and induce apoptosis in cancer cells, while minimizing toxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-cancer treatments are used to target Akt3 signaling cascade, iNOS, and MAP kinase pathways, then cancer cell survival and proliferation are inhibited, but systemic toxicity occurs and potency is insufficient
Solution Approach 1:
The patent applies local quality by designing selenium-containing compounds with specific molecular structures (Formula I and Formula II) that selectively target cancer cells exhibiting dysregulated Akt3, iNOS, and MAP kinase pathways. The compounds exploit the unique biochemical characteristics of cancer cells to achieve selective toxicity, thereby inhibiting cancer cell survival and proliferation while minimizing harm to normal cells with properly regulated pathways.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure from sulfur-containing analogs to selenium-containing compounds. This substitution alters key molecular parameters including bond lengths, bond angles, and electronic distribution, which enhances the compounds' ability to interact with and inhibit the dysregulated signaling pathways in cancer cells, thereby improving potency while reducing systemic toxicity.
2Reliability
If existing iNOS inhibitors are used to inhibit nitric oxide production, then apoptosis is induced, but cell permeability is poor and potency is low
Solution Approach 1:
The patent applies parameter changes by substituting sulfur with selenium in the molecular structure of iNOS inhibitors. This modification alters the physicochemical parameters of the compounds, including polarizability, bond strength, and molecular volume, which collectively enhance cell membrane permeability and intracellular delivery, thereby improving the induction of apoptosis in cancer cells.
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine selenium-containing moieties with pharmacophores specifically designed to target the Akt3-iNOS-MAP kinase signaling axis. These composite structures integrate multiple functional elements that work synergistically to improve cell permeability while maintaining potent iNOS inhibition and apoptosis induction.
3Productivity
If selenium-containing compounds are designed to inhibit Akt3 signaling cascade, then cancer cell proliferation is decreased, but selectivity against normal cells must be maintained
Solution Approach 1:
The patent applies local quality by designing selenium-containing compounds that specifically recognize and bind to dysregulated components of the Akt3 signaling cascade in cancer cells. The compounds exploit local biochemical abnormalities in cancer cells, such as overexpressed or constitutively active signaling molecules, to achieve selective inhibition of cancer cell proliferation while sparing normal cells with properly regulated pathways.
Solution Approach 2:
The patent employs intermediary mechanisms by using selenium-containing compounds as mediators that selectively interfere with the dysregulated Akt3-iNOS-MAP kinase signaling pathway in cancer cells. The compounds act as molecular intermediaries that disrupt pathological signaling interactions without affecting normal cellular signaling, thereby achieving selective anti-proliferative effects.
Data Source
AI summary
Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R—R1, where R is phenyl, where R1 is (CH2)n—Se—C(═NH)—NH2, where R2 is (CH2)n—Se—C(═NH)—NH2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.